Pacira BioSciences, Inc.
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
About Pacira BioSciences
Pharmaceutical Preparations, SIC 2834
Pacira BioSciences develops and commercializes non-opioid pain therapies for patients undergoing surgical procedures or managing chronic joint conditions. The company provides three primary commercial products: EXPAREL, a long-acting injectable local analgesic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device that administers targeted cold temperatures to relieve nerve pain without drugs. Its therapies serve surgical patients, including adult and pediatric populations, as well as individuals suffering from osteoarthritis and chronic musculoskeletal pain.
The business operates corporate headquarters and principal executive offices in Brisbane, California. It maintains commercial authorization and clinical registrations across the United States, Canada, and the European Union. In addition to commercializing products for hospital outpatient departments and ambulatory surgery centers, the enterprise oversees registry studies across 15 participating clinical sites in the United States.
Summary of the business section of Pacira BioSciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pacira BioSciences, Inc.
- Founded
- 2006
- Headquarters
- Brisbane, CA
- Address
- 2000 Sierra Point Parkway, Suite 900 94005
- Phone
- (650) 242-8052
- Employees
- 829, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Short Hills, NJ
Stock & identifiers
- Ticker
- PCRX
- Exchange
- Nasdaq
- IPO date
- Feb 3, 2011
- Shares outstanding
- 40M, Aug 3, 2026
- Public float
- $757.50M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1396814
- CUSIP
- 695127100
- ISIN
- US6951271005
- LEI
- 549300P56LERYBDHCF69
- EIN
- 51-0619477
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Frank D. Lee | Chief Executive Officer, Director | 660,831 |
| Jonathan Slonin | Chief Medical Officer | 216,384 |
| Lauren Riker | Senior Vice President, Finance | 62,284 |
| Kristen Williams | Chief Administrative Officer | 167,062 |
| Shawn Cross | Chief Financial Officer | 105,341 |
| Brendan Teehan | Chief Commercial Officer | 100,934 |
| Daryl Gaugler | Chief Operating Officer | 115,443 |
| Marcelo Bigal | Director | 17,798 |
| Michael J. Yang | Director | 19,798 |
| Thomas G. Wiggans | Director | – |
| Laura Brege | Director | 30,120 |
| Mark Froimson | Director | 26,541 |
| Christopher Christie | Director | 23,059 |
| Samit Hirawat | Director | 6,405 |
| Alethia Young | Director | 17,798 |
| Mark A. Kronenfeld | Director | 31,065 |
| Abraham Ceesay | Director | 9,039 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 David Stack | $727.38K | -$2.65M | $2.59M | $42 | $94 |
| FY2024 Frank Lee | $15.94M | $10.19M | $2.59M | $42 | $94 |
| FY2023 David Stack | $6.88M | $4.21M | $1.54M | $74 | $91 |
| FY2022 David Stack | $6.85M | $887.12K | $2.03M | $85 | $90 |
| FY2021 David Stack | $6.94M | $5.46M | $2.06M | $133 | $140 |
| FY2020 David Stack | $9.34M | $13.55M | $2.45M | $132 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 829 employees, of which 825 were full-time and four were part-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 19, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 22, 2021 | Tender offer | Third-party tender offer for the company's shares |
| Apr 9, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 9, 2019 | Name change | Name changed from Pacira Pharmaceuticals, Inc. to Pacira BioSciences, Inc. |
| Feb 26, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 18, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 3, 2011 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 28, 2011 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 5, 2008 | Name change | Name changed from PACIRA INC to Pacira Pharmaceuticals, Inc. |
| Apr 16, 2007 | Name change | Name changed from Blue Acquisition Corp to PACIRA INC |